Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic diseaseArticle Published on 2022-12-012023-07-11 Journal: RMD Open [Category] COVID19(2023년), [키워드] Arthritis, Rheumatoid Autoimmune diseases COVID-19 rituximab vaccination [DOI] 10.1136/rmdopen-2022-002650 PMC 바로가기
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center ExperienceResearch Article Published on 2022-12-012024-09-04 Journal: Turkish Journal of Hematology [Category] 대상포진, [키워드] Biosimilar diffuse large B-cell lymphoma Non-Hodgkin Lymphoma Redditux rituximab [DOI] 10.4274/tjh.galenos.2022.2022.0142 PMC 바로가기 [Article Type] Research Article
Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional studyArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 바이오마커, 진단, [키워드] Active disease ANCA-associated vasculitis Care clinical manifestations Cohort conducted COVID-19 COVID-19 infection COVID-19 severity Critical cross-sectional Cyclophosphamide death demographic died Disease activity Features Follow-up General population Immunosuppressant increased risk India Infection managing moderate non-COVID-19 patient not differ ocular outcome Patient patients patients died predicted receiving regimen required risk of COVID-19 rituximab SARS-CoV-2 severity single-center Supplemental oxygen therapy the patient Treatment Univariate analysis Vasculitis [DOI] 10.1007/s00296-022-05177-2 PMC 바로가기
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patientsArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval Affect anti-CD20 anti-CD20 treatment antibody Antibody Response Antibody titers B cell B cells B-cell B-cell depletion Blood booster cellular response Cohort correlated detectable develop Efficacy Guidance humoral identify IgG^{+} interleukin-13 Logistic regression median memory multiple sclerosis naïve no correlation Odds ratio Patient patients predict predictor Probability recent rituximab S1 domain SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seroconversion T-cell Response treated Treatment turn vaccination vaccine responses [DOI] 10.1111/ene.15492 PMC 바로가기
Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximabArticle Published on 2022-11-012022-11-15 Journal: International journal of urology : official journa [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome affected antibody antigen-specific T cell baseline cellular response Control controls coronavirus coronavirus disease COVID-19 demonstrated Deterioration dose enrolled enzyme-linked immunospot enzyme-linked immunospot assay evaluated healthcare worker healthy control humoral immunogenicity kidney Kidney function kidney transplant recipient kidney transplant recipients Kidney transplantation lack low-dose mRNA mRNA vaccine multivariate regression analysis not affect not significantly different profiles rituximab SARS-CoV-2 Seroconversion seroconversion rate Spike protein systemic adverse event the vaccine treatment history vaccination Vaccine [DOI] 10.1111/iju.14978 PMC 바로가기
Clinical features and outcomes of opsoclonus myoclonus ataxia syndromeArticle Published on 2022-11-012023-06-01 Journal: European journal of paediatric neurology : EJPN : [Category] A형 간염, [키워드] Acute lymphoblastic leukemia children Opsoclonus myoclonus ataxia syndrome Parainfectious Paraneoplastic rituximab [DOI] 10.1016/j.ejpn.2022.09.002
Prevalence and management of chronic hepatitis B in pemphigus and pemphigoid patients: New evidence for the safety of rituximabArticle Published on 2022-11-012023-06-12 Journal: Dermatologic therapy [Category] B형 간염, [키워드] Chronic Hepatitis B HBV Immunosuppression pemphigoid pemphigus rituximab [DOI] 10.1111/dth.15783
Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as MechanismArticle Published on 2022-10-292022-11-15 Journal: Military Medicine [Category] 진단, [키워드] Activation acute respiratory syndrome adverse effect chilblains coronavirus COVID disease infusion interferon mechanism Pfizer presenting rituximab significantly skin lesion Toe Vaccine worsened [DOI] 10.1093/milmed/usab314 PMC 바로가기
Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based studyArticle Published on 2022-10-082022-11-15 Journal: BMC Neurology [Category] COVID19(2023년), SARS, 진단, [키워드] adjusted collected conducted Control control group COVID-19 General population greater Hospitalization Hospitalized individual Infection Multiple multiple sclerosis Patient patients positive COVID-19 Positive test Primary infection Reinfection required Retrospective study risk rituximab SARS-CoV-2 SARS-CoV-2 test severity statistically significant difference tested Two patient [DOI] 10.1186/s12883-022-02907-8 PMC 바로가기
Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX)Article Published on 2022-10-062022-11-15 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Ad26.COV2.S ANCA-associated vasculitis anti-CD20 antibody antibody level Antibody titre approved AZD1222 B cell B-cell B-cells blood sample case-control study CD19+ COVID-19 COVID-19 vaccine dose ELISA evaluated examined Factor first vaccination Frame help humoral humoral immune response immunogenicity Immunoglobulin Improved increased risk Inflammatory International mAb Moderna outcomes parameter Patient quantified RA reduced regimen rheumatic disease rituximab RNA-1273 RTX SARS-CoV-2 severe COVID-19 synchronization the patient therapeutic therapy treated Treatment Univariate analysis vaccination Vaccine [DOI] 10.1093/rheumatology/keac036 PMC 바로가기